First Startup Company
Research on autologous, adipose derived stem cells by Dr. Adam Katz and Shayn Peirce-Cottler has led to critically important therapies for diabetics. "Dr. Katz and his collaborators have developed potentially game-changing technology for the treatment of diabetic wounds and other common afflictions," said Miette H. Michie, executive director and CEO of the U.Va. Patent Foundation. The work was licensed to a startup co-founded by Dr. Katz and colleagues.
UVA-Coulter start-up HemoShear enters into an agreement with Takeda Pharmaceutical Company that could be worth as much as $470 million. The two companies will use HemoShear’s proprietary disease modeling platform to discover and develop novel therapeutics for liver diseases.
Takeda and HemoShear Therapeutics Extend Exclusive Drug Discovery Partnership in Liver Diseases
Dexcom, TypeZero and the University of Virginia have had a longstanding, productive relationship in developing important technologies for diabetes management, including inControl for integration with both automated insulin delivery (“AID”) and smart pens. The companies share a consistent vision to improve the lives of people with diabetes through innovation.
DexCom Acquires TypeZero Technologies
UVA Coulter’s Early Technology is Licensed
A UVA team developed a training kit for otoscopy, a commonly performed procedure in the ear. The first of its kind, the team partnered with the medical education company Nasco. Through this relationship, the team has manufactured and distributed this important product to clinical training programs around the world.
Partnership with Siemens
The Department of Biomedical Engineering is a world leader in MRI research. With Coulter funding as well as support from the NIH, Siemens, and the UVA Medical School, Craig Meyer, John Mugler, and others have developed cutting edge imaging techniques for the heart, lung, brain, and other parts of human anatomy. In partnership with Siemens, a world leader in medical imaging, the project teams are able to implement their life saving technologies to the clinic.